Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PRKCA | P17252 | 4/20 | 0.59 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20717835 | 0.94 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL13778894 | 0.92 | ALDH1A1 (0.71) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL3685618 | 0.92 | ALDH1A1 (0.71) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL21479791 | 0.91 | ALDH1A1 (0.75) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL22681323 | 0.88 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL12677746 | 0.85 | ALDH1A1 (0.67) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL13778897 | 0.85 | PRKCA (0.76) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL13866563 | 0.84 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL19102029 | 0.84 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL31112785 | 0.84 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572605-B2 | 1,2,3,tris(4-hydroxy-butyroyloxy)propane; enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, and target specific organs | ORPHAN MEDICAL, INC. (US) | 2009-08-11 | — | — | US | claimed |
| US-20050250848-A1 | 1,2,3,tris(4-hydroxy-butyroyloxy)propane; enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, and target specific organs | ORPHAN MEDICAL, INC. | 2005-11-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250848-A1 | 1,2,3,tris(4-hydroxy-butyroyloxy)propane; enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, and target specific organs | SHBG, GHRHR, THRB | ALDH1A1 1954/4885LMNA 2966/4885PRKCA 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.